Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug hope for rare joint tumor patients who Can't have surgery

NCT ID NCT04703322

Completed Disease control Sponsor: Daiichi Sankyo Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a drug called pexidartinib (TURALIO) in 9 Japanese adults with tenosynovial giant cell tumor (TGCT), a rare, non-cancerous growth in the joints that causes pain and limits movement. The goal was to see if the drug is safe and can shrink tumors in people whose tumors are too severe or risky to remove with surgery. Participants took 800 mg of pexidartinib daily, and researchers measured tumor response using MRI scans.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
pexidartinib (TURALIO)
What this could lead to
If successful, this could provide a non-surgical treatment option for people with TGCT who have severe symptoms and cannot have surgery.
What could go wrong
This is a small, early-phase study with only 9 participants, so results may not apply to everyone. Pexidartinib can cause serious side effects, including liver injury.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TENOSYNOVIAL GIANT CELL TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Giant Cell Tumor of Tendon Sheath tenosynovial giant cell tumor tenosynovial giant cell tumor, diffuse type

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TENOSYNOVIAL GIANT CELL TUMOR

Contacts and locations

Locations

  • Kanazawa University Hospital

    Ishikawa, 920-8641, Japan

  • Kyushu University Hospital

    Fukuoka, 812-8582, Japan

  • Nagoya University Hospital

    Aichi, 466-8560, Japan

  • National Cancer Center Hospital

    Tokyo, 104-0045, Japan

  • National Hospital Organization Osaka National Hospital

    Osaka, 540-0006, Japan

  • Osaka International Cancer Institute

    Osaka, 541-8567, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.